# US 2021/0196827 A1 · Functional nucleic acid having nucleoside analog drug integrated into skeleton, derivative and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196827 A1
- Document ID: US20210196827A1
- Status: Published application
- Kind: A1
- Application number: 17/057,525
- Filed: 2018-12-14
- Published: 2021-07-01
- Earliest claimed: 2018-05-21
- Applicants: Shanghai Jiaotong University
- Inventors: Chuan ZHANG; Yuan MA; Quanbing MOU; Xinyuan ZHU
- Web page: https://patentgrep.com/patent/US20210196827A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/318: where the PO2 is completely replaced, e.g. MMI or formacetal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The application discloses a functional nucleic acid having nucleoside analog drug integrated into skeleton, a derivative, and preparation methods thereof wherein the derivative is obtained by conjugating or self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with one of a polymer, a hydrophobic molecule, and a transfection reagent. Compared with the prior art, the functional nucleic acid having nucleoside analog drug integrated into skeleton and the derivative thereof can efficiently enter cells and be used to regulate genes; subsequently, the functional nucleic acid having nucleoside analog drug integrated into skeleton can be degraded by nuclease and release active ingredient of the nucleoside analog drug, thus playing a role in chemotherapy. Hence, the functional nucleic acid having nucleoside analog drug integrated into skeleton and the derivative thereof can simply and efficiently realize a combination therapy of gene therapy and chemotherapy, and a complex synthesis procedure is avoided.

## Claims

### Claim 1

A functional nucleic acid having nucleoside analog drug integrated into skeleton, wherein the nucleoside analog drug is integrated into the skeleton of the functional nucleic acid by replacing natural nucleotides in the functional nucleic acid after chemical modifications:
wherein the ratio of gene drugs and chemotherapeutic drugs is able to be precisely controlled by adjusting the number of natural nucleotides replaced by the nucleoside analog drugs;
wherein the functional nucleic acid is selected from antisense oligonucleotides, small interfering RNA, messenger RNA, microRNA, long non-coding RNA, small hairpin RNA, guide RNA for gene editing, and circular RNA;
wherein the nucleoside analog drug is selected from purine analogs, guanosine analogs, cytidine analogs, adenosine analogs and uridine analogs.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The functional nucleic acid having nucleoside analog drug integrated into skeleton according to claim 1, wherein a method for preparing the functional nucleic acid having nucleoside analog drug integrated into skeleton is selected from the followings:
using a phosphoramidite monomer of the nucleoside analog drug, preparing a functional nucleic acid having nucleoside analog drug integrated into skeleton by solid-phase synthesis method; and
using a triphosphate monomer of the nucleoside analog drug, preparing a functional nucleic acid having nucleoside analog drug integrated into skeleton by in vitro enzyme transcription method or PCR amplification.

### Claim 8 (depends on 7)

The functional nucleic acid having nucleoside analog drug integrated into skeleton according to claim 7, wherein the method comprising the following steps:
inputting the sequence of the functional nucleic acid to be synthesized into a solid-phase synthesizer, and preparing the functional nucleic acid having nucleoside analog drug integrated into skeleton on the surface of ordinary CPG or an amino-modified CPG;
reacting a mixed solution of RNA polymerase, template DNA, RNA nucleoside triphosphate monomer, triphosphate monomer of nucleoside analog drug, and reaction buffer at 37° C. to prepare the functional nucleic acid having nucleoside analog drug integrated into skeleton; and
reacting a mixed solution of DNA polymerase, template DNA, DNA primer, DNA nucleoside triphosphate monomer, triphosphate monomer of nucleoside analog drug, and reaction buffer at 37° C. to prepare the functional nucleic acid having nucleoside analog drug integrated into skeleton.

### Claim 9 (depends on 1)

A derivative of the functional nucleic acid having nucleoside analog drug integrated into skeleton according to claim 1, wherein the derivative is selected from the followings:
a functional derivative that formed by combining the functional nucleic acid having nucleoside analog drug integrated into skeleton with a molecular targeting group;
a derivative and a self-assembled nanostructure thereof that obtained by modifying the functional nucleic acid having nucleoside analog drug integrated into skeleton with a polymer or a hydrophobic molecule;
a derivative of composite nanostructure that obtained by self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with a transfection reagent; and
a derivative of composite nanostructure that obtained by self-assembling the functional nucleic acid modified by a polymer or a hydrophobic molecule with a transfection reagent.

### Claim 10 (depends on 9)

The derivative according to claim 9, wherein a method for preparing the derivative of the functional nucleic acid having nucleoside analog drug integrated into skeleton is selected from the followings:
using targeting molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using polymers to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using hydrophobic molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with a transfection reagent to obtain a derivative of composite nanostructure; and
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton or modified product thereof that modified by polymers or hydrophobic molecules with the transfection reagent to obtain a derivative of composite nanostructure.

### Claim 11 (depends on 10)

The derivative of the functional nucleic acid having nucleoside analog drug integrated into skeleton according to claim 10, wherein the method using polymer modification comprises the following steps:
providing a degradable polymer with an azide group at the terminus synthesized by ring-opening polymerization, and then carrying out a copper-free catalytic click reaction between the degradable polymers and the functional nucleic acid having nucleoside analog drug integrated into skeleton modified by diphenyl-cyclooctyne, obtaining a conjugate of the degradable polymer-functional nucleic acid having nucleoside analog drug integrated into skeleton, as one of the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton.

### Claim 12 (depends on 1)

A method for treating-diseases based on the combination of gene therapy and chemotherapy, wherein the method uses the functional nucleic acid having nucleoside analog drug integrated into skeleton according to claim 1 and/or derivatives thereof.

### Claim 13 (depends on 9)

The derivative according to claim 9, wherein a method for preparing the functional nucleic acid having nucleoside analog drug integrated into skeleton is selected from the followings:
using a phosphoramidite monomer of the nucleoside analog drug, preparing a functional nucleic acid having nucleoside analog drug integrated into skeleton by solid-phase synthesis method; and
using a triphosphate monomer of the nucleoside analog drug, preparing a functional nucleic acid having nucleoside analog drug integrated into skeleton by in vitro enzyme transcription method or PCR amplification.

### Claim 14 (depends on 9)

The derivative according to claim 9, wherein a method comprising the following steps:
inputting the sequence of the functional nucleic acid to be synthesized into a solid-phase synthesizer, and preparing the functional nucleic acid having nucleoside analog drug integrated into skeleton on a surface of ordinary CPG or an amino-modified CPG;
reacting a mixed solution of RNA polymerase, template DNA, RNA nucleoside triphosphate monomer, nucleoside analog drug triphosphate monomer, and reaction buffer at 37° C. to prepare the functional nucleic acid having nucleoside analog drug integrated into skeleton; and
reacting a mixed solution of RNA polymerase, template DNA, RNA primer, nucleoside analog drug triphosphate monomer, and reaction buffer at 37° C. to prepare the functional nucleic acid having nucleoside analog drug integrated into skeleton.

### Claim 15 (depends on 13)

The derivative according to claim 13, wherein the method for preparing the derivative of the functional nucleic acid having nucleoside analog drug integrated into skeleton is selected from the followings:
using targeting molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using polymers to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using hydrophobic molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with a transfection reagent to obtain a composite nanostructure derivative; and
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton or modified product thereof that modified by polymers or hydrophobic molecules with the transfection reagent to obtain a derivative of composite nanostructure.

### Claim 16 (depends on 14)

The derivative according to claim 14, wherein the method for preparing the derivative of the functional nucleic acid having nucleoside analog drug integrated into skeleton is selected from the followings:
using targeting molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using polymers to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using hydrophobic molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with a transfection reagent to obtain a composite nanostructure derivative; and
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton or modified product thereof that modified by polymers or hydrophobic molecules with the transfection reagent to obtain a derivative of composite nanostructure.

### Claim 17 (depends on 15)

The derivative according to claim 15, wherein the method using polymer modification comprises the following steps:
providing a degradable polymer with an azide group at the terminus synthesized by ring-opening polymerization, and then carrying out a copper-free catalytic click reaction between the degradable polymers and the functional nucleic acid having nucleoside analog drug integrated into skeleton modified by diphenyl-cyclooctyne, obtaining a conjugate of the degradable polymer-functional nucleic acid having nucleoside analog drug integrated into skeleton, as one of the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton.

### Claim 18 (depends on 16)

The derivative according to claim 16, wherein the method using polymer modification comprises the following steps:
providing a degradable polymer with an azide group at the terminus synthesized by ring-opening polymerization, and then carrying out a copper-free catalytic click reaction between the degradable polymers and the functional nucleic acid having nucleoside analog drug integrated into skeleton modified by diphenyl-cyclooctyne, obtaining a conjugate of the degradable polymer-functional nucleic acid having nucleoside analog drug integrated into skeleton, as one of the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton.

### Claim 19 (depends on 12)

The method according to claim 12, wherein the method for preparing the functional nucleic acid having nucleoside analog drug integrated into skeleton is selected from the followings:
using a phosphoramidite monomer of the nucleoside analog drug, preparing a functional nucleic acid having nucleoside analog drug integrated into skeleton by solid-phase synthesis method; and
using a triphosphate monomer of the nucleoside analog drug, preparing a functional nucleic acid having nucleoside analog drug integrated into skeleton by in vitro enzyme transcription method or PCR amplification.

### Claim 20 (depends on 12)

The method according to claim 12, wherein the method comprising the following steps:
inputting the sequence of the functional nucleic acid to be synthesized into a solid-phase synthesizer, and preparing the functional nucleic acid having nucleoside analog drug integrated into skeleton on a surface of ordinary CPG or an amino-modified CPG;
reacting a mixed solution of RNA polymerase, template DNA, RNA nucleoside triphosphate monomer, nucleoside analog drug triphosphate monomer, and reaction buffer at 37° C. to prepare the functional nucleic acid having nucleoside analog drug integrated into skeleton; and
reacting a mixed solution of RNA polymerase, template DNA, RNA primer, nucleoside analog drug triphosphate monomer, and reaction buffer at 37° C. to prepare the functional nucleic acid having nucleoside analog drug integrated into skeleton.

### Claim 21 (depends on 12)

The method according to claim 12, wherein the derivative is selected from the followings:
a functional derivative that formed by combining the functional nucleic acid having nucleoside analog drug integrated into skeleton with a molecular targeting group;
a derivative and a self-assembled nanostructure of the derivative that obtained by modifying the functional nucleic acid having nucleoside analog drug integrated into skeleton with a polymer or a hydrophobic molecule:
a derivative of composite nanostructure that obtained by self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with a transfection reagent; and
a derivative of composite nanostructure that obtained by self-assembling a product with a transfection reagent, wherein the product is obtained by modifying the functional nucleic acid having nucleoside analog drug integrated into skeleton with a polymer or a hydrophobic molecule.

### Claim 22 (depends on 12)

The method according to claim 12, wherein the method for preparing the derivative of the functional nucleic acid having nucleoside analog drug integrated into skeleton is selected from the followings:
using targeting molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using polymers to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
using hydrophobic molecules to modify the functional nucleic acid, obtaining the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton;
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with a transfection reagent to obtain a composite nanostructure derivative; and
self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton or modified product thereof that modified by polymers or hydrophobic molecules with the transfection reagent to obtain a derivative of composite nanostructure.

### Claim 23 (depends on 12)

The method according to claim 12, wherein the method of modifying with polymers comprising the following steps:
providing a degradable polymer with an azide group at the terminus synthesized by ring-opening polymerization, and then carrying out a copper-free catalytic click reaction between the degradable polymers and the functional nucleic acid having nucleoside analog drug integrated into skeleton modified by diphenyl-cyclooctyne, obtaining a conjugate of the degradable polymer-functional nucleic acid having nucleoside analog drug integrated into skeleton, as one of the derivatives of the functional nucleic acid having nucleoside analog drug integrated into skeleton.
